Sharp Therapeutics Corp. has reported new preclinical data supporting its novel therapeutic approach for Niemann-Pick disease type C (NPC).
Sharp Therapeutics Corp. has reported new preclinical data supporting its novel therapeutic approach for Niemann-Pick disease type C (NPC).